Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;49(10):1487-1494.
doi: 10.1038/ng.3940. Epub 2017 Aug 21.

A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor

Samantha Gadd  1 , Vicki Huff  2 , Amy L Walz  3 , Ariadne H A G Ooms  1   4 , Amy E Armstrong  3 , Daniela S Gerhard  5 , Malcolm A Smith  6 , Jaime M Guidry Auvil  5 , Daoud Meerzaman  7 , Qing-Rong Chen  7 , Chih Hao Hsu  7 , Chunhua Yan  7 , Cu Nguyen  7 , Ying Hu  7 , Leandro C Hermida  5 , Tanja Davidsen  7 , Patee Gesuwan  5 , Yussanne Ma  8 , Zusheng Zong  8 , Andrew J Mungall  8 , Richard A Moore  8 , Marco A Marra  8   9 , Jeffrey S Dome  10 , Charles G Mullighan  11 , Jing Ma  11 , David A Wheeler  12 , Oliver A Hampton  12 , Nicole Ross  13 , Julie M Gastier-Foster  13 , Stefan T Arold  14 , Elizabeth J Perlman  1
Affiliations

A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor

Samantha Gadd et al. Nat Genet. 2017 Oct.

Abstract

We performed genome-wide sequencing and analyzed mRNA and miRNA expression, DNA copy number, and DNA methylation in 117 Wilms tumors, followed by targeted sequencing of 651 Wilms tumors. In addition to genes previously implicated in Wilms tumors (WT1, CTNNB1, AMER1, DROSHA, DGCR8, XPO5, DICER1, SIX1, SIX2, MLLT1, MYCN, and TP53), we identified mutations in genes not previously recognized as recurrently involved in Wilms tumors, the most frequent being BCOR, BCORL1, NONO, MAX, COL6A3, ASXL1, MAP3K4, and ARID1A. DNA copy number changes resulted in recurrent 1q gain, MYCN amplification, LIN28B gain, and MIRLET7A loss. Unexpected germline variants involved PALB2 and CHEK2. Integrated analyses support two major classes of genetic changes that preserve the progenitor state and/or interrupt normal development.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Genetic Landscape of Favorable Histology Wilms Tumor
Data variables of interest (rows) for 76 FHWT samples (columns) are separated into six clusters according to gene expression. Upper panel: Rows 2, 3, 4 provide NMF cluster according to gene expression, DNA methylation, or microRNA expression, respectively. Row 5 provides gene expression subset according to expression patterns previously reported [1]. These are followed by the most highly recurrently mutated genes, copy number changes, and methylation status at 11p15 as determined by 450K data. The predominant pre-treatment histological classification of the tumor (blastemal, stromal, or epithelial for those showing these patterns in >66% of the tumor represented in all slides, and mixed for those lacking a predominant histologic pattern), and the presence of accompanying nephrogenic rests (perilobar, PLNR, and intralobar, ILNR) are also provided. Lower panel: Illustrates the expression of genes of interest, with red and blue indicating relatively high and low expression, respectively. Genes present in the top 100 GSEA ranked list for each cluster that overlapped with genes from lists significantly enriched by GSEA in the same cluster are illustrated. Also provided are genes associated with the pre-induction and post-induction metanephric mesenchyme (MM) and genes associated with Wnt signalling in the early developing kidney.
Figure 2
Figure 2. 11p15 ICR1 and ICR2 methylation and select miRNA expression patterns
A. 11p15 Imprinting Status: Graphical representation of the average DNA methylation beta values for 11p15 imprinting control region 1 (ICR1; x axis) and ICR2 (y axis) in 78 FHWT. Retention of imprinting (ROI) is defined as ICR1 and ICR2 average beta values of 0.3–0.7; loss of imprinting (LOI) is defined as 0.8–1 for ICR1 and 0.3–0.7 for ICR2; loss of heterozygosity (LOH) is defined as 0.8–1 for ICR1 and 0–0.2 for ICR2. B. miRNA-10a and -10b expression: Box plots representing miRNA-10a (top panel) and -10b (bottom panel) expression in FHWT. The maximum (top whisker), the 75th, median, and 25th percentiles (box), and minimum expression values (bottom whisker) were calculated for FHWT with MLLT1 mutation (n = 7) and FHWT without MLLT1 mutation (n = 71) by using miRNAseq reads per kilobase of transcript per million mapped reads (RPKM) data. Two-tailed p-values were calculated by using unpaired t-tests assuming unequal variance. Upper panel: p = 4.2×10-7, t = 5.531, df = 76. Lower panel: p = 3.7×10-6, t = 4.987, df = 76. C. Let7a expression: Box plots representing let7a expression in FHWT in gene expression clusters 1 and 2 (N=38) compared with clusters 3 and 4 (N=28). The maximum, 75th percentile, median, 25th percentile, and minimum expression values were calculated by using microRNAseq RPKM data (top) or using RT-PCR to measure mature let7a normalized to RNU44 previously reported [3] (bottom). Two-tailed p-values were calculated by using unpaired t-tests assuming unequal variance. Upper panel: p = 0.01, t = 2.654, df = 64. Lower panel: p = 0.002, t = 3.22, df = 64.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gadd S, et al. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: A Children's Oncology Group study. Neoplasia. 2012;14:742–756. - PMC - PubMed
    1. Torrezan GT, et al. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat Commun. 2014;5:4039. - PMC - PubMed
    1. Wegert J, et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type WTs. Cancer Cell. 2015;27:298–311. - PubMed
    1. Rakheja D, et al. Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun. 2014;5:4802. - PMC - PubMed
    1. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms Tumor Study. Cancer. 1978;41:1937–48. - PubMed